A homology model of human CYP27B1 was built using MOE and ith further optimisation by molecular dynamics simulations of the hCYP27B1 homology model and a hCYP27B1-SDZ-88357 complex. Docking results from the hCYP27B1-SDZ-88357 complex showed amino acids Arg107, Asn387 and Asp320 have an important role in binding interaction, with Asp320 part of the important acid -alcohol pair situated in the I-helix with the conserved sequence (A/G) GX (E/D) (T/S), which assumes an essential role in the binding of an oxygen molecule for catalysis.
Introduction
Calcitriol (1,25-dihydroxyvitamin D3) is the biologically active form of vitamin D, with deficiency of calcitriol in human linked to defects in bone formation and mineralisation, for example, rickets in children and osteomalacia in adults 1 . CYP27B1 (vitamin D 1α-hydroxylase), which is expressed primarily in the kidney 2 but is also found in other organs, 3 produces calcitriol by 1-hydroxylation of 25-hydroxyvitamin D3 (Figure 1 ).
Figure 1. Vitamin D metabolic pathway
Calcitriol subsequently binds to the vitamin D receptor (VDR) to enhance production of target genes 4, 5 . Calcitriol is subject to metabolic transformation to inactive polar metabolites by the action of CYP24A1 (vitamin D 24-hydroxylase). Under normal conditions levels of CYP27B1 and CYP24A1, and therefore the levels of calcitriol, are tightly controlled through the action of parathyroid hormone and fibroblast growth factor-23 6, 7 . However, increased levels of CYP24A1
have been observed in a number of human cancers including breast 8 , colon 9 , prostate 10 and skin cancers 11 , directly correlating with a reduction in circulating calcitriol. To enhance circulating levels of the biologically active form of vitamin D, CYP24A1 inhibitors have been developed [12] [13] [14] [15] [16] [17] [18] [19] and, although potent inhibitors with IC50 values in the nanomolar range have been described, one of the biggest challenges has been designing inhibitors selective for CYP24A1 over CYP27B1. A few azole inhibitors with good selectivity have been described, notably (R)-VID400 12 which is ~ 40-fold more selective for CYP24A1 compared with CYP27B1 and the SDZ compounds, SDZ-88357 12 and SDZ-285082 13 , which are ~ 166-fold and 47-fold respectively more selective for CYP27B1 over CYP24A1 (Fig. 2) .
(R To date crystal structures for human CYP24A1 (hCYP24A1) and human CYP27B1 (hCYP27B1)
have not been resolved. A model of hCYP24A1 using the rat CYP24A1 (rCYP24A1) crystal structure as a template has previously been described by our group 14, 20 . To assist in the design of a selective CYP24A1 inhibitor, a human hCYP27B1 homology model was required in order to analyse any differences between active site architecture and binding interactions of the two enzymes. A hCYP27B1 hybrid homology model, built by combining models generated from rCYP24A1 and hCYP11A1 crystal structures as templates, has been described by Zalewski et al 21 in their investigation of mutations in hCYP27B1 related to vitamin D dependent rickets type I. In a similar manner suitable templates were identified and homology models were generated for our research but with the focus on active site binding/architecture for the purpose of drug design.
Results and discussion

Generation of the hCYP27B1 homology model
Using the UniProt KB/TrEMBL server (ExPASy) 22 the complete human CYP27B1 protein sequence (entry number O15528), composed of 508 amino acids, was selected. A protein-protein BLAST 23 (ncbi) search was run against the Protein Databank (PDB) 24 to identify homologous crystal structures. The most homologous templates were rCYP24A1 and hCYP11A1 with 33% sequence identity, however the rCYP24A1 template had greater sequence coverage, higher BLAST score and E-value (Table 1) . (Fig. 3) . Conservation was clearly observed between most of the residues of the query sequence and the closely related templates in the active site region, which encompasses the haem binding domain typically sandwiched between helix L on the side of the haem proximal to the surface of the protein and helix I in the inside of the protein as well as the important acid-alcohol pair situated in the I-helix with the conserved sequence (A/G) GX (E/D) (T/S) (Fig. 3 ).
H HELIX acid-alcohol I Helix J Helix CYP11A1
LGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQ Homology models using both rCYP24A1 and hCYP11A1 were generated using MOE software and based on validation results using Ramachandran plots 26 , Verify 3D 27 and ProSA 28 , as well as BLAST analysis and consideration of template enzyme function, the homology model from rCYP24A1 as template was chosen for further optimisation and docking studies.
Molecular dynamics studies
Further optimisation of the active site architecture was achieved by molecular dynamics simulations, using the Desmond programme of Maestro 29 , carried out at two different temperatures, 300 K and 312 K. Molecular dynamics simulation at 300 K and 312 K represent normal body temperature and elevated body temperature.
Molecular dynamics of hCYP27B1 model at 300K
The RMSD values of the backbone atoms were plotted as a time-dependent function of the molecular dynamics simulation. The outcomes support the CYP27B1 model structure, as they show time dependence of constant RMSD (Å) of the backbone atoms throughout the whole simulation process. This demonstrates that the model achieved equilibrium after some initial fluctuations. The chart plainly shows that there is an adjustment in the RMSD from 0.9 Å to 2.4 Å and that it reached 2.02 Å at 1.39 ns and then declined to 1.83 Å at 1.83 ns, but after that, it reached a plateau from showed the differences of structural behaviours and flexibilities in each residue for the CYP27B1 model; the amino acid residue (Gly281) was shown to be highly fluctuated.
Molecular dynamics of hCYP27B1 model at 312 K
The RMSD of the backbone atom values for CYP27B1 at 312 K simulations were not much different from the simulations at 300 K. However, the graph clearly indicates that there is a change in the RMSD from 0.9 Å to 2.5 Å, and it reaches a plateau from 2.48 ns ( Fig. 4C and 4D ). Overall, it can be said that there is no significant difference in structure during molecular dynamics simulations at temperatures 300 K and 312 K. This means that at 312 K, the model still has activity, and no structural damage has occurred.
To validate the optimised hCYP27B1 model structure, Ramachandran plots were run before as well as after molecular dynamics simulation. The number of outlier amino acids after molecular dynamics was 5 (1.1%) compared with 12 (2.5%) amino acid outliers prior to molecular dynamics.
The five outliers were found to be in the outer regions of the protein within loops, which are very difficult to model, and away from the active site. Protein interactions with the ligand were checked throughout the simulation and interactions are ordered by their type; specifically hydrogen bonds, hydrophobic, ionic, and water bridges (Fig. 6 ).
Molecular dynamic simulation of the hCYP27B1-SDZ-88357 complex at 300 K
Figure 6.
Illustration of protein interactions with the ligand. The red column means ionic bond, green column a hydrogen bond, blue column water bridges, and a purple column a hydrophobic bond. The stacked bar charts are normalised over the course of the trajectory: for example, a value of 0.5 suggests that for 50% of the simulation time, the specific interaction is maintained.
Interaction between the nitrogen lone pair of the tetrazole ring of SDZ-88357 and the haem iron at a distance of 2.25 Å was observed with hydrophobic interactions with amino acid residues in the active site (Phe110, Leu127, Pro385 and Gly386) (Fig. 7) . In addition, SDZ-88357 was observed making three additional hydrogen bonds with amino acids Arg107, Asn387 and Asp320. form an interaction with the imidazole ring of this CYP24A1 inhibitor, and no H-bonding interaction formed with the hydrophobic 4-chlorobiphenyl side chain ( Fig. 8A and B) . However SDZ-285082 docked favourably with hydrogen bonding interactions with Arg107 and Asn387 as observed for SDZ-88357 ( Fig. 8C and D) . 
Docking of SDZ-88357 in the hCYP24A1 model and a triple mutant hCYP24A1 model
Schuster et al. 4 showed that SDZ-88357 was a very weak inhibitor of the CYP24A1 enzyme (> 10 There were multiple hydrophobic interactions between the SDZ-88357 with amino acid residues in the active site (Arg128, Leu129, Ile131, Trp134, Leu148, Met246, Phe249, Leu325, ala326, Val391, Pro392, Phe393, Thr395, His497, Gly499 and Thr500) (Fig. 9A ) but no hydrogen bonding interactions within the hCYP24A1 hydrophobic active site cavity. SDZ-285082 docked in a similar manner and was also positioned too far from the haem iron (4.15Å) to interact (Fig. 9B) . This was in contrast with (R)-VID400 with the distance between the nitrogen of imidazole and the haem iron observed as 2.31Å (Fig. 9C) .
To explore the potential importance of H-bonding interactions in the inhibitory activity and selectivity of SDZ-88357 in hCYP27B1, a computational triple hCYP24A1 mutant was generated using MOE software 30 . After alignment of the hCYP24A1 and hCYP27B1 3D models, amino acids of hCYP24A1 that were comparable in position with Arg107, Asp320 and Asn387 were identified 
Design and synthesis of hCYP27B1 inhibitors
With the new findings regarding hCYP24A1 vs hCYP27B1 requirements for selectivity, further evaluation of optimal pharmacophores was reconsidered and through combining key binding requirements (haem binding, H-bonding functional group) the 4,4'-((3/4-(pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) structures (1a and 1b) were designed to explore binding/inhibition profiles. 1a and 1b displayed interesting results in the docking experiments with hCYP24A1 and hCYP27B1 and could be generated using a short efficient synthetic route. When 1a and 1b were docked in the hCYP24A1 model, interaction with the haem iron was through the pyridyl nitrogen with hydrogen bonding with Arg128, Leu129, Glu130, Leu148 and Thr395 as illustrated in Figure 11A . The docking would predict CYP24A1 inhibitory activity, with the longer pyridin-4-ylmethoxy group allowing close binding with the haem, however the hydrophilic functional groups with resulting hydrogen bonding would suggest CYP27B1 inhibitory activity.
Docking of 1a and 1b in the hCYP27B1 model did indicate good fit, hydrogen bonding interactions (Asp320 and Asn387, identified as important for CYP27B1 inhibitory activity) and haem binding, although in the hCYP27B1 model haem binding was optimal through a pyrazole nitrogen (Fig.   11B ).
The designed compounds (1) were readily obtained in two steps. The 3/4-(pyridine-4-ylmethoxy)benzaldehydes (3) were prepared as previously described 31 
CYP24A1 and CYP27B1 enzymatic assay
The CYP24A1 enzymatic assay followed methodology previously described 33 . In short, human
CYP24A1 with an N-terminal fusion to maltose binding protein (MBP) was overexpressed in
Escherichia coli and purified to homogeneity. The hydrolase activity was reconstituted in vitro, and the resulting cell-free assay system was applied in the screening of the compounds to measure IC50
The inhibition assay of CYP27B1 was similar to the CYP24A1 assay as previously described 33 , and the resulting cell-free assay system was applied in the screening of the compounds to measure IC50.
The main difference between 1a and 1b was changing the position of the ether group from the para position to the meta position on the phenyl ring, but it resulted in no notable difference in CYP24A1 or CYP27B1 inhibitory activity. 1a and 1b displayed modest CYP24A1 inhibitory activity compared with the standard ketoconazole (KTZ, IC50 0.5 M), however as expected from docking they displayed potent CYP27B1 inhibitory activity comparable with KTZ (IC50 0.34 M) with IC50 0.57 and 0.41 M respectively.
Figure 12. hCYP24A1 and hCYP27B1 inhibitory activity
1a and 1b have selectivity for CYP27B1 that is ~ 5-fold greater than CYP24A1 (Fig. 12) . The selectivity of 1a and 1b can be rationalised by better fit and binding in the hCYP27B1 active site, where the pyrazole ring interacted with the haem iron in addition to formation of hydrogen bonds with Asp320 and Asn387, which are important amino acids in hCYP27B1.
Conclusions
A homology model of CYP27B1 was built using MOE and was evaluated for stereochemical and amino acid environment quality using appropriate programmes, with further optimisation of the 
Experimental
General Experimental
1,25(OH)2D3 and 25(OH)D3 were purchased from SAFC-Pharma (Madison, WI). Human MBP-CYP24A1, CYP27B1, bovine adrenodoxin (Adx), and adrenodoxin reductase (AdR) were purified as described previously 33 . All solvents used for chromatography were HPLC grade from Fisher Scientific (UK).
H and 13
C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with Me4Si as internal standard. Mass spectra and microanalysis were determined by the MEDAC (Chobham, UK). Flash column chromatography was performed with silica gel 60 (230-400mesh) (Merck) and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by illumination under UV light (254 nm) or by the use of vanillin stain followed by charring on a hotplate. Melting points were determined on an electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 4Å molecular sieves, under nitrogen. All compounds were more than 95% pure.
Molecular modelling
Homology search
The protein sequence for hCYP27B1 was obtained from the ExPASy proteomics server at the Swiss Bioinformatics Institute 22 . The enzyme sequence for the hCYP27B1 has the Uniprot identifier O15528 and is composed of 508 amino acids. A homology search was performed using protein BLAST accessible from the NCBI website 23 , which was used to align the query sequence (hCYP27B1) against the sequences in the protein data bank 24 and thus the close homologous proteins were identified. The alignment parameters and the thresholds, which were used for screening expected homologues, were used with their default values and BLOSUM62 comparison matrix.
3D model building
The molecular experiments were performed using Molecular Operating Environment (MOE)
2014.0901 molecular modeling software 30 . Homology models were built using MOE-Homology using AMBER99 forcefield 34 , which uses a dictionary to set the partial charges of atoms in amino acids. The final homology model was constructed using rCYP24A1 (3K9V-A) and hCYP11A1 (3N9Y) crystal structure. Ten intermediate models were generated and the final model was taken as the Cartesian average of all the intermediate models. All minimisations were performed until RMSD gradient of 0.05 kcal mol -1 Å -1 with the specified forcefield and partial charges automatically calculated.
Model validation
Stereochemical quality of the polypeptide backbone and side chains was evaluated using Ramachandran plots obtained from the RAMPAGE server 26 . The compatibility of the 3D model with its own amino acid 1D sequence was examined using Verify 3D 27 . The ProSA server 28 was used to check defaults in the three dimensional protein structure based on statistical analysis.
Validation data from the templates (3K9V-A and 3N9Y) was used as the baseline to evaluate the model.
Molecular dynamics simulation
A molecular dynamics simulation was run on the hCYP27B1 model alone and the CYP27B1 model 
Docking
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT 35 . The important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500) 20 were selected and then the selection was extended to 12 Å in order to include in the docking site the haem iron region and the access tunnel to the catalytic site. A ligands database in mol2 format, prepared using MOE 30 , was used as input for the docking calculations. The iron atom of the catalytic site was set as essential pharmacophoric feature. Ligand docking was performed using the default values and no water molecules were considered. Ten output solutions were obtained from each compound and visual inspection in MOE was used to identify the interaction between ligand and protein. 
4,4'-((4-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) (1a).
Tan crystalline solid obtained after recrystallization from methanol. Yield: 36%; Rf 0.34 (CH2Cl2- 
4,4'-((3-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) (1b)
Tan crystalline solid obtained after recrystallization from methanol. Yield: 25%; Rf 0.75 (EtOAc- 
Enzymatic assays
Inhibition of hCYP24A1 was performed as previously described 33 . each compound was performed in at least duplicate and in triplicate for compounds with good inhibitory properties. Inhibition assay of hCYP27B1 was performed in a way similar to that of CYP24A1 as previously described 33 .
Supplementary material
Supplementary data associated with this article can be found, in the online version, at ……… Clustal analysis; Model validation -Ramachandran, Verify3D, ProSA ; Secondary structure prediction; Synthesis of 2-HEAP and 3a and 3b.
